CNBX — CNBX Pharmaceuticals Balance Sheet
0.000.00%
- $0.38m
- $1.56m
Annual balance sheet for CNBX Pharmaceuticals, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1.39 | 0.118 | 0.13 | 0.026 | 0.015 |
| Prepaid Expenses | |||||
| Total Current Assets | 1.59 | 0.198 | 0.224 | 0.031 | 0.018 |
| Net Property, Plant And Equipment | 0.643 | 0.437 | 0.275 | 0 | 0 |
| Long Term Investments | |||||
| Total Assets | 3.08 | 0.811 | 0.499 | 0.031 | 0.018 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.27 | 2.44 | 2.52 | 2.51 | 2.51 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.27 | 2.44 | 2.52 | 2.51 | 2.51 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.81 | -1.63 | -2.02 | -2.48 | -2.5 |
| Total Liabilities & Shareholders' Equity | 3.08 | 0.811 | 0.499 | 0.031 | 0.018 |
| Total Common Shares Outstanding |